Publications

Kelley RK, Bracci P, Gordan JD, Behr SC, Quandt Z, Atreya CE, Kidder WA, Ko AH, Lim HC, Van Loon K, Adeniji N, Venook AP, Fong L, Keenan BP. A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 42599167

Gould P, Coskey D, Ma X, Wang S, Godbole S, Bond D, Ip A, Ananth S, Varma S, Ayers E, Faden R, Gillespie C, William B, Jacobs R, Hu B, Lattin J, Russler-Germain D, Stanchina M, Rose A, Randall M, Spinner M, Srikakulapu V, Geethakumari PR, Skarbnik A, Chitty DW, Tsang M, Duarte C, Major A, Bock AM, Baron K, Hess B, Tolu S, Pro B, Vaidya S, Amengual JE, Reshef R, Cherng HJ. Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes. Haematologica. 2026. PMID: 42610418

Liu Q, Chen PA, Urs E, Zhang S, Arce MM, Wang CH, Yan J, Nguyen VQ, Li Z, Seo J, Kale N, Peng F, Luo Y, Goudy L, LaFlam TN, Zhong H, Modak C, Dann E, Jung JH, Kirane A, Warner AB, Quach BB, Good Z, Shy BR, Shifrut E, Bapat SP, Allen GM, Eyquem J, Fuh K, Dodgson SE, Cyster JG, Marson A, Carnevale J. In vivo genome-wide CRISPR screens of human T cells in solid tumours. Nature. 2026. PMID: 42587162

Nagpal S, Carlson-Clarke B, Rout SS, Trinh TTH, Roy-O'Reilly M, Tedjakusuma SN, Taiwo R, Harary PM, Granucci M, Chernikova SB, Bertrand S, Therkelsen KE, Han SS, Gu B, Bharani KL, Newman JM, Barisano G, Umeh-Garcia MC, Herrick D, Vogel H, Arora M, Samos CH, Soltys SG, Pollom EL, Rahimy E, Iv M, Melisko ME, Hayden Gephart M. Phase 2 test of QBS72S for breast cancer leptomeningeal disease. Neuro-oncology. 2026. PMID: 42565554

Norouzi A, Johnson K, Avelar K, Civantos A, Ilan A, Durr ML, Patel Y, Paciorek A, Zhang L, Eltawil Y, Alqasieer Y, Kim K, Graham J, Ha P, Chan J, Yom SS, Ross L, Li S, Brodie S, Xu MJ. Post-Radiation Dental Care Access Among Head and Neck Cancer Survivors: A Safety Net Perspective. Laryngoscope investigative otolaryngology. 2026. PMID: 42568617

Rugo HS, Ryan JC. P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2- Metastatic Breast Cancer in the USA-A Vodcast. Targeted oncology. 2026. PMID: 42560565

Bui TBV, Wolf DM, Bruck MC, Moore K, Lien J, Choi SDW, Warhadpande S, Parizadeh A, Dillon D, Overmoyer B, Lynce F, Brown-Swigart L, Hirst GL, Yau C, I-SPY2 Investigators, Nijman IJ, Burgering BMT, Harris IS, Esserman LJ, van 't Veer LJ, Rosenbluth JM. Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer. Cell reports. Medicine. 2026. PMID: 42561946

Rasche L, Schinke C, Touzeau C, Minnema MC, van de Donk N, Rodriguez-Otero P, Mateos MV, Ye JC, Tomlinson C, Vishwamitra D, Singh I, Qin X, Campagna M, Masterson T, Vreys V, Lau BW, Tolbert J, Renaud T, Heuck C, Chari A. Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study. Blood. 2026. PMID: 42561120

Gu D, Chakravarty D, Cuby J, Hall S, Stitzer M, Kushel M, Xia F, Vijayaraghavan M. Contingency Management for Smoking Cessation Among Adults Experiencing Homelessness: A Pilot Randomized Clinical Trial. JAMA network open. 2026. PMID: 42579279

Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerer HM, Lee MC, Moran MC, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Veer LJV, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA. Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial. Annals of surgical oncology. 2026. PMID: 42545411

Stevenson J, Riely GJ, Wood DE, Aisner DL, Axtell AL, Bauman JR, Bharat A, Chang JY, Desai A, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Levy B, Lin J, Loo BW, Lovly CM, Maldonado F, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patil T, Polanco PM, Riess J, Ruano Mendez AL, Shapiro TA, Singh AP, Tam A, Tanvetyanon T, Yanagawa J, Yau E, Yun K, Gregory K, Hang L. Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 42607715

Rugo HS, Schmid P, Cortes J, Takano T, Fasching PA, Park YH, Bianchini G, Franco SX, Villarreal-Garza C, Tredan O, Yin Y, Barroso-Sousa R, Peng X, Malhotra U, Smith KL, Bardia A. TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future oncology (London, England). 2026. PMID: 42535874

Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerrer HM, Lee MC, Moran MC, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Van't Veer LJ, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA. ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial. Annals of surgical oncology. 2026. PMID: 42536241

Isaacs C, Nanda R, Yau C, Chien AJ, Hershman DL, Stringer-Reasor EM, Wallace AM, Thomas A, Vaklavas C, Clark AS, Kennedy LC, Sanford A, Boughey JC, Albain KS, Pusztai L, Kalinsky KM, Beckwith H, Williams NO, Han HS, Falkson C, Arora M, Elias AD, Pohlmann PR, Rozenblit M, Marshall N, Chen YY, Trivedi MS, McGuinness JE, Howard FM, Chen N, Khoury K, Lancaster RB, Yeung KT, Douglas E, Wei M, Mainor C, LeStage B, Delson AL, Asare AL, Brown-Swigart L, Hirst GL, Matthews JB, Perlmutter J, Symmans WF, Yee D, Hylton NM, van 't Veer LJ, Rugo HS, DeMichele AM, Berry DA, Esserman LJ. Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial. JAMA oncology. 2026. PMID: 42530945

Pecoraro G, De Giorgi A, Montelatici G, Salfi G, Lin HM, Turco F, Taha T, Beltran H, de Bono J, Aggarwal RR, von Amsberg G, Joerger M, Imbimbo M, Colombo I, Gillessen S, Pedrani M. DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives. Drugs. 2026. PMID: 42527846

Magbanua MJM, Wolf DM, Yau C, Manon NA, Sayaman RW, Brown Swigart L, Hirst G, Li W, Isaacs C, Shatsky R, Clark AS, Zimmer A, Mukhtar R, Delson AL, Perlmutter J, Pohlmann PR, Hylton NM, Nanda R, Yee D, Symmans WF, Esserman LJ, Rugo HS, DeMichele A, van 't Veer LJ. Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy. medRxiv : the preprint server for health sciences. 2026. PMID: 42619946

Wang B, Zou C, Zhang X, Fu L, Liu K, Song H, Wang G, Xie S, Zeng J, He S, Ai W, Wan L, Liu Y, Pan S, Li Y, Deng H, Yang F, Lu Y, Tang W, Fu X, Li J. Prevalence and correlates of depressive symptoms among young men who have sex with men: The role of family functioning and loneliness. Acta psychologica. 2026. PMID: 42520712

Stefan DC, Dee EC, Ting FIL, Buckle GC. Rethinking cancer control in low- and middle-income countries: from workforce expansion to systems transformation. BMC cancer. 2026. PMID: 42509545

Borate UM, Huang Y, Lin TL, Handa S, Swords R, Lachowiez CA, Traer E, Stock W, Odenike O, Patel AA, Baer MR, Duong VH, Stein EM, Blum W, Vale CA, Curran E, Madanat YF, Olin RL, Schiller GJ, Nichols AD, Williams L, Heerema NA, Johnson MF, Chen TL, Marcus S, Martycz M, Stefanos M, Rosenberg L, DeGennaro LJ, Gruenbaum L, Burd A, Byrd JC, Druker BJ, Levine RL, Yocum AO, Mims AS, Zeidner JF. OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML. Blood. 2026. PMID: 42520193

Paller CJ, Freitas K, Macario N, Tran C, Faville K, Wiedemer K, Chiang J, Lorentz J, Appleman LJ, Armstrong AJ, Barata PC, Borno HT, Crawford K, DeMarco TA, Dreicer R, Elrod JAB, Gabram S, George C, Heath EI, Hussain A, Hussain MHA, Neil JM, Mao S, McKay RR, Morgans AK, Ogunsanya ME, Orton M, Ritchie T, Saraiya B, Sokolova AO, Szmulewitz R, Fortt I, Ramos L, Smith S, Freeman P, McMannis A, Green R, Vinson J, Cheng HH. Recruitment strategies in the PROMISE Registry: Evaluating institutional outreach, direct-to-patient marketing, and community engagement approaches in a decentralized germline genetic registry. Contemporary Clinical Trials Communications. 2026. PMID: 42569313